137 results about "Anticarcinogenic Effect" patented technology

The invention discloses a preparation method and application of roasted barley and malt polysaccharide with an anti-cancer effect. The roasted barley malt polysaccharide is a neutral heteropolysaccharide which mainly takes-> 3)-beta-D-Glcp-(1-> and->-beta-D-Glcp-(1->) as main chains, branches exist at O-3 / O-4 positions, and the branch chains are mainly composed of-> 4)-beta-D-Xylp-(1->,-> 3, 4)-beta-D-Xylp-(1-> and alpha-D-Glcp-(1->. The monosaccharide composition comprises arabinose, glucose and xylose in a molar mass ratio of 1.86: 33.43: 1.00, and the molecular weight is 23.81 kDa. In-vitro activity experiments prove that the roasted barley malt polysaccharide disclosed by the invention has a remarkable inhibition effect on proliferation of liver cancer cells, lung cancer cells, breast cancer cells and colorectal cancer cells, particularly on the liver cancer cells, and shows outstanding anti-tumor activity, so that the roasted barley malt polysaccharide is expected to be developed and applied in the fields of foods, health-care products or medicines.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

[Problem] To provide a novel compound promising as a prodrug-type anticancer agent that exhibits a sufficient anticancer effect and is capable of reducing adverse effects. [Solution] A compound represented by general formula (I) or a pharmaceutically acceptable salt of the compound. Formula (I): Y-T-(X1)n

A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

The present invention provides extracellular vesicles isolated from stem cells treated with zymosan, Poly LC, and monophosphoryl lipid A (MPLA), their use for treatment of cancer, and a method for preparing the same. The extracellular vesicles according to the present invention contain various miRNAs and cytokines related to anticancer effects, and have tumor growth inhibitory effects. In addition, since the extracellular vesicles exhibit a synergistic effect in cancer treatment when administered in combination with an immune checkpoint inhibitor, a pharmaceutical composition for cancer treatment containing the extracellular vesicles as an active ingredient is highly likely to be effectively useful in cancer treatment by increasing immune activity in the body.

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

The application discloses a combined drug for treating lung cancer. It is found for the first time that lomethixol can be used alone or in combination with other drugs to have a significant anticancer effect on NSCLC patients and NSCLC patients resistant to osimertinib, and in addition, it is found that lomethixol is a potential autophagy inducer and can activate cell autophagy. The application provides a new clinical treatment method for NSCLC patients and NSCLC patients resistant to osimertinib, and has a wide application prospect.

The present invention provides the use of chrysin to enhance the sensitization of VS4718 or ponatinib in the treatment of esophageal squamous cell carcinoma. The present invention finds that chrysin can enhance the growth inhibition and invasion inhibition of esophageal squamous cell carcinoma cells mediated by VS4718 or ponatinib, and can effectively enhance the tumor metabolism inhibition mediated by VS4718 or ponatinib. Chrysin is used in combination with VS4718 or ponatinib to produce a synergistic anti-cancer effect.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention relates to the technical field of biological medicines, and particularly discloses a compound, a preparation method thereof and application of the compound in preparation of a medicine with an anti-cancer effect. The compound has a structure as shown in a formula I which is described in the specification. Researches show that the compound has a remarkable inhibition effect on the growth of breast cancer and lung cancer cells; further researches show that the compound can also significantly inhibit migration and invasion of breast cancer and lung cancer cells. Therefore, the compound disclosed by the invention is used as an effective component for preparing the medicine with the effects of resisting breast cancer and lung cancer; particularly, the compound has important application value when being used for preparing medicines with effects of resisting metastasis and invasion of breast cancer and lung cancer cells.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

A system for evaluating the anticancer activity of a magnesium complex {[Mg(1,10-Phenanthroline)(H2O)4](1,3-Benzthiazol-2-thiolate) 2. 1,10-Phenanthroline} against oral squamous cell carcinoma, including: a cell culture apparatus configured to maintain human oral squamous cell carcinoma cells in a controlled environment with specific temperature and CO2 conditions; a compound delivery module configured to deliver predetermined concentrations of the magnesium complex to the cultured cells; a cell analysis unit configured to measure and analyze cellular responses to the magnesium complex; a flow cytometry device configured to analyze cellular parameters such as apoptosis and cell cycle progression; and a data processing unit configured to calculate and analyze cytotoxicity data and to generate inhibitory percentages.

The present invention provides the afatinib or a pharmaceutically salt thereof for use in the treatment and / or prevention of a cancer in a patient suffering from a disease caused by a defect in DNA damage repair mechanism. Surprisingly, when afatinib was administered to FA cells, it was confirmed that there was a therapeutic anti-cancer effect without any toxic side-effect on DNA.

The present disclosure relates to a method for preparing a cancer-specific T cell based on peripheral blood or a peripheral immune organ for preventing or treating cancer, specifically including steps of: first, isolating an immune cell from peripheral blood or the peripheral immune organ; then, co-incubating with a nanoparticle and / or a microparticle loaded with a tumor whole-cell antigen for a period of time to activate the cancer-specific T cell; then, isolating a cancer-specific T cell activated by the tumor antigen; and, reinfusing the cancer-specific T cell into the body to exert an anti-cancer effect after in vitro expansion. According to the nanoparticle or microparticle prepared by the present disclosure, a tumor antigen component is loaded onto the microparticle and / or the nanoparticle to activate the cancer-specific T cell, and then the cancer-specific T cell is expanded and reinfused into a patient for treating cancer or preventing recurrence or metastasis. The cancer-specific T cell isolated by a sorting method has high specificity, and may prevent or treat cancer by killing cancer cells after expansion.

The invention relates to a composition containing selenium gluconate and application of the composition in preparation of anti-cancer drugs. The composition comprises a shiitake mushroom extract, a chicory extract and selenium gluconate. Wherein the selenium gluconate is selenium salt of gluconic acid, has an anti-cancer effect, but is easy to generate side effects when being independently used; according to the invention, the mushroom extract, the chicory extract and the selenium gluconate are combined for use, so that the killing power of the composition on cancer cells can be synergistically improved, the immunity can be remarkably improved, the related side effects can be effectively reduced, and the damage to normal cells can be reduced.

The invention relates to the technical field of biological medicines, and particularly discloses a compound or a composition and application of the compound or the composition in preparation of a medicine with an anti-cancer effect. The compound has a structure as shown in a formula I, a formula II or a formula III. Researches show that the compound provided by the invention has an anti-pancreatic cancer effect; further research shows that the composition composed of the compounds with the structures as shown in the formula I and the formula III has a more excellent pancreatic cancer resisting effect, and the pancreatic cancer resisting effect of the composition is greatly higher than that of the single compound with the structure as shown in the formula I or the single compound with the structure as shown in the formula III.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

The present invention pertains to a composition, containing aripiprazole as an active ingredient, for enhancing the anticancer effect of a RAF inhibitor. More specifically, the present invention pertains to a composition for enhancing the anticancer effect of the RAF inhibitor, wherein the composition can treat cancer by acting as an agent for enhancing the anticancer effect of the RAF inhibitor when used in combination therapy with aripiprazole. Administering an effective amount of aripiprazole according to the present invention in combination with the RAF inhibitor is highly effective in enhancing the anticancer effect of the RAF inhibitor, such as by inducing cancer cell death, and thus the composition can be advantageously used as an agent for enhancing the anticancer effect of the RAF inhibitor.

The present invention relates to: an antibody targeting a mutation of KRAS as an intracellular oncoprotein; or a fusion protein in which a cancer cell-penetrating peptide is linked to a single-chain variable fragment of the antibody by a genetic expression method or a chemical bonding method; and a tumor therapeutic use thereof. The fusion protein thus produced has the benefit of maximizing an anti-tumor or anticancer effect of the antibody or the single-chain variable fragment of the antibody targeting an intracellular oncoprotein or an oncomutant protein by effectively invading tumor cells.

The invention relates to the field of biological science and drug carriers, in particular to tumor microenvironment enzyme response type nano-particles, a preparation method and application thereof, and the tumor microenvironment enzyme response type nano-particles comprise at least two structural domains a which are sequences of matrix metalloproteinase substrate peptides; at least one structural domain b which is a sequence of melittin; the structural domain a is connected to the C tail end and the N tail end of the structural domain b; the tumor microenvironment enzyme response type melittin can slowly release melittin in a tumor microenvironment under enzyme response to achieve an anti-cancer effect, can also be used for preparing a nano-drug, and can deliver a ferroptosis small-molecule accelerant RSL3 to the tumor microenvironment in a targeted manner, so that the drug can infiltrate into tumor cells and induce tumor cell death, and the tumor microenvironment enzyme response type melittin has a good anti-cancer effect. The antigens in tumor cells are released, so that tumor immunotherapy and tumor metastasis treatment are realized, and the drug resistance of liver metastatic tumors is eliminated.

The present invention addresses the problem of developing a drug for inhibiting the DNA damage restoration mechanism in a cancer which does not have a mutation in BRCA 1 / 2 and in which homologous recombination repair functions normally.　The inventors of the present invention have clarified that cell death can be induced by inhibiting PARP functions and mitochondrial respiration functions in cells, and indicated that the problem can be solved. In other words, the present invention provides: a method for inducing cell death by inhibiting PARP functions and mitochondrial respiration functions in cells; and a pharmaceutical composition for treating cancer, the pharmaceutical composition containing a PARP inhibitor and a mitochondrial respiration inhibitor.

The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to API5 according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.

The invention discloses application of dauricine in preparation of a medicine for treating non-small cell lung cancer, belongs to medical application of the dauricine in the technical field of biological medicines, and creatively discovers that the dauricine has an excellent effect of treating the non-small cell lung cancer. The proliferation of non-small cell lung cancer cells can be inhibited by reducing mitochondrial membrane potential, inhibiting Notch3 protein activity, reducing the expression level of DLL4 protein and the like; meanwhile, a good treatment effect is shown in a non-small cell lung cancer mouse model, growth and proliferation of non-small cell lung cancer cells can be remarkably inhibited, apoptosis of the non-small cell lung cancer cells is induced, depolarization of mitochondria of the non-small cell lung cancer cells is induced, Notch3 protein activity is remarkably inhibited, expression of DLL4 protein is reduced, and the anti-cancer effect is achieved. The invention provides a new path for the application of the dauricine in treating the non-small cell lung cancer, and provides a new thought and strategy for the development and utilization of the dauricine.

The present application relates to the field of immunology, in particular to anti-LILRB1 antibodies or antigen-binding fragments thereof, preparation methods and uses, especially anti-LILRB1 nanobodies or antigen-binding fragments thereof, preparation methods and uses. The anti-LILRB1 antibodies or antigen-binding fragments thereof can inhibit the immune escape mechanism of tumor cells, so that immune cells can exhibit their anti-cancer effects.

The present invention relates to the use of sodium pentaborate pentahydrate enriched with boron isotope (10B, 11B) as a chemotherapeutic agent thanks to its anticarcinogenic effect on renal cancer. As a result of the experimental studies performed within the scope of the invention, it has been shown that while the number of renal cancer cells decreased by 50%, this effect occurs by arresting the cell cycle and slowing down cell proliferation, therefore sodium pentaborate pentahydrate enriched with boron isotope can be used as a chemotherapeutic agent in cancer treatment.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

The present invention relates to the field of biomedicine technology, and specifically discloses a thiophene-containing pyrimidine compound, a preparation method thereof, and its use in the preparation of drugs with anti-cancer effects. The thiophene-containing pyrimidine compound has a chemical structure represented by formula (I). Studies have shown that the thiophene-containing pyrimidine compound has an inhibitory effect on PLK1 protein kinase; therefore, using it as an active ingredient in the preparation of drugs with anti-cancer effects has important application value. In particular, in existing anti-cancer experiments, the thiophene-containing pyrimidine compound has a better effect on non-small cell lung cancer than the known compound BI2536, showing a more significant anti-non-small cell lung cancer effect.